

PRESS RELEASE



nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTCQB:NDATF) announces positive Clinical Study results, and Mindbalanced update.

Calgary, Alberta – October 8, 2024 - *For Immediate Release* – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTCQB:NDATF) is pleased to announce the following updates:

Positive Clinical Study results:

The following chart predicts depression probabilities using two different approaches:

1. The original YMI “expert-guided” approach where the predictive scoring is guided by psychoanalytical experts *in advance* of the application of machine-learning; and
2. the “supervised” approach where *no expert guidance is provided in advance* of machine-learning application.

Predisposition for Depression, approach comparison

Model	YMI Expert guided	ML supervised	ML & DNA supervised
Statistical Significance (lower=better)	0.021	0.050	0.045
Accuracy	84%	81%	84%
Precision	86%	85%	90%
Recall	98%	75%	77%
F1 Score (best overall)	91%	80%	82%

The Chart shows that the machine-learning results support the YMI expert-guided results and that the YMI approach outperforms the machine-learning approach. Both approaches used the same “ground truth” targets (i.e. depression diagnoses by only Psychiatrists and Psychologists while excluding primary physician diagnoses). These excellent results support two product paths, both of which require only occasional machine-learning calibration, thereby reducing complexity and cost:

1. Advanced Digital Therapeutics (“DTx”) - an online platform for correlation of various data types used to design highly-personalized “on and off label” treatment protocols for multiple mental conditions and non-drug treatment modalities such as transcranial magnetic stimulation (TMS”), and Trigeminal Nerve Stimulation (eTNS), Seasonal Affective Disorder (“SAD”) Light Therapies. DTx product manufacturers are now being contacted; and
2. as an adjunctive mental health assessment tool (“YMI”) for use by primary care physicians and family doctors who are often a patient’s first contact with the mental health system and who are seeking advanced technologies to help significantly reduce depression mis/overdiagnoses that is believed to be a root cause of inappropriate prescribing and poor treatment outcomes. We believe that preferred point of entry is through electronic medical records (“EMR”) and the Corporation is now taking steps in this regard. The product, YMI, is online now and available for integration.

James Durward, President, commented, “From the beginning our goal was to combine the power of a purpose-built database with machine-learning to go beyond the limitations of human assessments and I believe we have accomplished this goal. We are also now in the position to correlate known outcomes from a variety of treatment modalities to predict higher-precision treatment protocols *before* treatment. We believe this to be the future of precision mental health assessment and treatment.”

Mindbalanced: Regarding the acquisition agreement dated April 15, 2024, the acquisition was completed in anticipation of Mindbalanced enrolling multiple TMS clinics, thereby providing a channel for YMI’s correlation to TMS treatment protocols, and entry into the US market. Since the acquisition closed, Mindbalanced clinic enrollment has not met expectations and the Corporation is currently negotiating the reversal of the transaction in a manner that reduces the current issued and outstanding common shares to the level immediately preceding the acquisition. It is anticipated there will be no material cost for doing so.

For Further Information, please contact:

Jim Durward, President, CEO/CTO
Email: jjimd@ndatalyze.com
nDatalyze Website: <https://www.ndatalyze.com>

About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual’s predisposition toward a variety of common mental conditions, both current and forward in time. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns societal impact with financial success.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes

certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.